Table 3.
AEs according to according to arms. BR arm: initial BR followed by cisplatin-pemetrexed ChT combined with bevacizumab for eligible patients. ChT arm: cisplatin-pemetrexed ChT combined with bevacizumab for eligible patients with BR only at cerebral disease progression.
| BR arm n = 45 (%) | ChT arm n = 46 (%) | |||||||
|---|---|---|---|---|---|---|---|---|
| Gr 1 | Gr 2 | Gr 3 | Gr 4 | Gr 1 | Gr 2 | Gr 3 | Gr 4 | |
| Anemia | 5 (22.) | 13 (29) | 3 (7) | − | 7 (15) | 8 (17) | 5 (11) | 1 (2) |
| Anorexia | − | 2 (4) | 2 (4) | − | 5 (11) | 1 (2) | − | − |
| Neutropenia | 3 (7) | 11 (24) | 2 (4) | 4 (9) | 3 (7) | 6 (13) | 10 (22) | 3 (6) |
| Asthenia | 9 (20) | 17 (38) | 4 (9) | − | 19 (41) | 8 (17) | 3 (7) | 1 (2) |
| Headache | 8 (178) | 3 (7) | − | − | 4 (9) | 2 (4) | − | − |
| Renal failure | 5 (22.) | 4 (9) | − | 1 (2) | 3 (7) | 4 (8) | 1 (2) | − |
| Diarrhea | 6 (13.) | 2 (4) | − | − | 1 (2) | 1 (2) | 1 (2) | − |
| Dysgeusia | 3 (7) | − | − | − | 3 (7) | − | − | − |
| Epistaxis | 3 (7) | 3 (7) | − | − | 2 (4) | 1 (2) | − | − |
| Arterial hypertension | − | 2 (4) | 1 (2) | − | 1 (2) | 1 (2) | − | − |
| Mucositis | 2 (4.) | − | − | 1 (2) | − | 2 (4) | − | |
| Nausea | 12 (27) | 5 (22) | 1 (2) | − | 14 (29) | 7 (15) | − | − |
| Vomiting | 5 (22) | 3 (7) | 2 (4) | 1 (2) | 3 (7) | 5 (10) | 2 (4) | − |
AE, adverse event; BR, brain radiotherapy; ChT, chemotherapy.